How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

How Chemotherapy Induced DNA Damage Shapes Anti-Tumor Immunity

Abstract

DNA-damaging chemotherapies remain foundational in cancer treatment and are increasingly recognized as potent modulators of anti-tumor immunity. Genotoxic stress activates innate immune sensing pathways, most prominently the cGAS–STING axis, resulting in type I interferon production, immunogenic cell death, and the priming of adaptive immune responses. Paradoxically, these same processes drive immunosuppressive mechanisms within the tumor microenvironment, including ENPP1-mediated degradation of extracellular cGAMP and the consequent accumulation of adenosine. These suppressive pathways restrict dendritic cell activation, impair effector T-cell function, and diminish natural killer cell cytotoxicity, thereby limiting durable therapeutic responses. The dynamic molecular and cellular interplay between cGAS–STING signaling and the ENPP1–adenosine axis ultimately shapes the balance between immune activation and immune suppression following chemotherapy, highlighting the importance of strategies that modulate these convergent pathways to improve clinical outcomes.

Introduction

Historically, cytotoxic chemotherapies were viewed as immunosuppressive agents due to their lymphodepleting effects and systemic toxicity. Over the past decade, however, this concept has shifted substantially. It is now evident that many DNA-damaging chemotherapies engage the immune system through immunogenic cell death (ICD), release of danger-associated molecular patterns (DAMPs), and activation of innate immune sensing pathways.

At the same time, accumulating evidence demonstrates that DNA damage also initiates compensatory immunosuppressive programs that restrain anti-tumor immunity. Among these, enzymatic degradation of cGAMP by ENPP1 and consequent accumulation of extracellular adenosine represent central mechanisms by which tumors dampen immune activation following genotoxic stress. These pathways operate at the intersection of innate immune sensing, metabolic regulation, and immune checkpoint control. Understanding how chemotherapy-induced DNA damage simultaneously promotes immune activation and immune suppression is critical for rational therapeutic design.

DNA Damage and Innate Immune Sensing in Cancer

Cytosolic DNA Formation as a Consequence of Chemotherapy-Induced Genotoxic Stress
Chemotherapeutic DNA-damaging agents, including platinum-based compounds, topoisomerase inhibitors, and alkylating agents, exert their antitumor effects by inducing extensive genotoxic stress characterized by DNA adduct formation, replication fork stalling, and double-strand breaks (DSBs). When DNA damage exceeds the capacity of repair pathways, cells undergo aberrant mitosis and chromosome mis-segregation, leading to genomic instability and the generation of micronuclei. These micronuclei are encapsulated by structurally fragile nuclear envelopes that are prone to rupture during interphase or upon mechanical stress. Envelope disruption results in the release of enclosed double-stranded DNA (dsDNA) into the cytosol, thereby breaching the spatial segregation between nuclear DNA and cytoplasmic innate immune surveillance mechanisms. Cytosolic dsDNA is predominantly sensed by cyclic GMP–AMP synthase (cGAS), which binds dsDNA in a sequence-independent manner and becomes catalytically activated to synthesize the second messenger 2′3′-cyclic GMP–AMP (cGAMP). This process establishes a direct molecular link between chemotherapy-induced genomic instability and the activation of innate immune signaling pathways.

Activation of the cGAS–STING Pathway by Damaged DNA
Upon binding to cytosolic double-stranded DNA, cGAS catalyzes the synthesis of the cyclic dinucleotide 2′3′-cGAMP, which functions as a potent second messenger. cGAMP subsequently binds to the adaptor protein STING (stimulator of interferon genes), which is localized to the endoplasmic reticulum membrane. Ligand engagement induces a conformational change in STING that promotes its oligomerization and trafficking from the endoplasmic reticulum to the ER–Golgi intermediate compartment and Golgi apparatus. During this translocation, STING serves as a signaling platform for the recruitment and activation of TANK-binding kinase 1 (TBK1), leading to phosphorylation and activation of interferon regulatory factor 3 (IRF3). Activated IRF3 translocates to the nucleus, where it drives the transcription of type I interferons and interferon-stimulated genes, resulting in a robust innate immune response.

Type I interferon signaling is a critical mediator of anti-tumor immunity, as it promotes the maturation and activation of dendritic cells, enhances antigen processing and cross-presentation, and supports efficient priming and expansion of cytotoxic CD8⁺ T cells. In parallel, STING activation engages the NF-κB pathway, leading to the production of pro-inflammatory cytokines and chemokines that further shape the tumor immune microenvironment and facilitate immune cell recruitment.

Intercellular Signaling
In addition to cell-intrinsic activation, cGAS–STING signaling can propagate across cell boundaries through the intercellular transfer of the second messenger cGAMP. Tumor cells experiencing chemotherapy-induced genotoxic stress can export cGAMP to neighboring immune cells via gap junctions or dedicated cGAMP transport mechanisms. This horizontal transfer enables paracrine activation of antigen-presenting cells, including dendritic cells and macrophages, even in the absence of direct DNA sensing. Paracrine activation amplifies type I interferon production, enhances antigen presentation capacity, and promotes immune cell maturation, thereby extending innate immune activation beyond the primary site of DNA damage. Through this mechanism, localized chemotherapy-induced cytosolic DNA sensing is translated into a broader, systemic antitumor immune response.

Table 1. Chemotherapeutic Drug Classes That Induce DNA Damage and an Immune Response

Drug Class	Mechanism of DNA Damage	Characteristics of Damaged DNA	Immune Response
Platinum compounds (Cisplatin)	DNA crosslinking (mainly intra-strand guanine–guanine adducts)	Bulky DNA adducts, helix distortion, stalled transcription/replication	Induces ICD and increases neoantigen load; DNA damage can generate cytosolic DNA and cGAS–STING pathway activation
Topoisomerase II inhibitors (Doxorubicin, Etoposide)	Stabilization of Topo II–DNA cleavage complexes cause DSBs	Persistent DSBs, chromosomal fragmentation, micronuclei formation	Strong ICD inducers; micronuclei activate cGAS–STING, driving type I interferon signaling
Radiomimetic antibiotics (Bleomycin)	Free-radical–mediated DNA strand breaks	Single- and double-strand breaks resembling ionizing radiation damage	DNA fragments leak into cytosol inducing innate immune sensing (STING) and pro-inflammatory cytokine production
Antimetabolites (5-Fluorouracil)	Misincorporation into DNA/RNA and thymidylate synthase inhibition	Base mismatches, replication stress, stalled forks	Enhances tumor immunogenicity by increasing antigen presentation and selectively depleting immunosuppressive myeloid cells
PARP inhibitors (Olaparib)	Inhibition of single-strand break repair induces collapsed forks and DSBs	Accumulated unrepaired DNA lesions, chromosomal instability	Cytosolic DNA accumulation activates cGAS–STING, synergizing strongly with immune checkpoint blockade

Chemotherapy-Induced Innate and Adaptive Anti-Tumor Immunity

Chemotherapy Induced Innate Immune Activation in Tumors

Chemotherapy-induced DNA damage triggers robust activation of the innate immune system within the tumor microenvironment, engaging multiple immune and stromal cell populations. Tumor cells experiencing genotoxic stress accumulate cytosolic DNA, leading to activation of the cGAS–STING pathway and the production of type I interferons and other inflammatory mediators. These signals act both in an autocrine manner and on surrounding immune cells. Dendritic cells sense tumor-derived cGAMP and interferons, resulting in upregulation of costimulatory molecules, enhanced antigen processing, and migration to tumor-draining lymph nodes where they prime tumor-specific T cells.

Natural killer cells are activated indirectly through interferons and inflammatory cytokines, as well as directly through the recognition of stress-induced ligands expressed on damaged tumor cells, promoting early cytotoxic responses and shaping subsequent adaptive immunity. In parallel, macrophages undergo functional reprogramming toward pro-inflammatory, antigen-presenting phenotypes characterized by increased cytokine and chemokine production, thereby supporting effector cell recruitment and amplifying local immune activation. Collectively, these chemotherapy-induced innate immune responses transform the tumor microenvironment into a pro-immunogenic niche that is essential for effective adaptive immune priming and durable antitumor immunity.

Immunogenic Cell Death, Antigen Availability and Adaptive Immune Priming

Several DNA-damaging chemotherapeutic agents induce immunogenic cell death (ICD), a regulated form of tumor cell demise that actively promotes antitumor immunity rather than immune tolerance. ICD is characterized by the emission of damage-associated molecular patterns. These signals function as potent “eat-me” and activation cues for antigen-presenting cells, enhancing phagocytic uptake of dying tumor cells, promoting dendritic cell maturation, and stimulating inflammasome and pattern-recognition receptor signaling.

Concomitantly, chemotherapy increases both the abundance and diversity of tumor-derived antigens, including neoantigens generated by genomic instability, thereby improving antigen availability for immune surveillance. The integration of enhanced antigen release with type I interferon signaling and dendritic cell activation facilitates efficient cross-presentation and robust priming of tumor-specific CD8⁺ T cells in tumor-draining lymph nodes. Activated effector T cells subsequently traffic to the tumor site, exert cytotoxic activity against residual malignant cells, and contribute to the establishment of long-lasting immunological memory. Consistent with these mechanisms, durable clinical responses to chemotherapy are increasingly associated with the strength and persistence of adaptive immune responses, underscoring the adaptive immune-mediated component of chemotherapeutic efficacy.

Counter-Regulatory Immunosuppression Following DNA Damage

ENPP1 as an Immune Regulator

ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) functions as a critical immune regulator that constrains innate immune activation following DNA damage. By hydrolyzing extracellular cGAMP into AMP, which is subsequently converted into adenosine, ENPP1 limits signaling within the tumor microenvironment. Many tumors upregulate ENPP1 in response to genotoxic and inflammatory stress, effectively dampening activation in stromal and immune cells. Through this dual function, ENPP1 simultaneously attenuates interferon-driven inflammation and promotes the accumulation of immunosuppressive adenosine, positioning it as a mechanism of immune resistance following chemotherapy

The Extracellular Adenosine Pathway

Chemotherapy-induced tumor cell death results in the release of extracellular nucleotides that are sequentially metabolized by CD39, ENPP1, and CD73, culminating in the accumulation of extracellular adenosine within the tumor microenvironment. Adenosine acts as a potent immunosuppressive metabolite by engaging A2A and A2B receptors expressed on T cells, natural killer cells, dendritic cells, and myeloid populations. Receptor engagement activates cAMP-dependent signaling cascades that inhibit T-cell receptor signaling, suppress pro-inflammatory cytokine production, impair cytotoxic granule release, and stabilize regulatory T-cell phenotypes. In parallel, adenosine signaling reprograms myeloid cells toward tolerogenic and suppressive states, including M2-like macrophages and myeloid-derived suppressor cells, thereby dampening antigen presentation and reinforcing immune exclusion. Collectively, the extracellular adenosine pathway that favors immune evasion rather than durable antitumor immunity.

Targeting ENPP1 and Adenosine Signaling to Restore Anti-Tumor Immunity

ENPP1 Inhibition

Pharmacologic inhibition of ENPP1 amplifies DNA damage–induced innate immune responses, while simultaneously blocking immunosuppression. By preventing the extracellular degradation of cGAMP, ENPP1 inhibitors prolong activation in antigen-presenting cells and other immune populations within the tumor microenvironment, resulting in sustained type I interferon production and enhanced inflammatory signaling. In parallel, blockade of ENPP1 limits the generation of AMP, thereby reducing downstream adenosine accumulation and its suppressive effects on effector immune cells. Preclinical studies demonstrate that ENPP1 inhibition synergizes with DNA-damaging therapies to increase dendritic cell activation, improve antigen cross-presentation, and promote robust infiltration and functionality of tumor-specific CD8⁺ T cells. Although ENPP1 inhibitors remain in early stages of clinical development, their ability to couple enhancement of innate immune activation with attenuation of immune inhibition positions them as a compelling strategy for durable antitumor immunity.

Adenosine Pathway Blockade

Therapeutic blockade of the extracellular adenosine pathway provides a complementary approach to overcoming immune suppression in tumors exposed to genotoxic stress. Multiple agents targeting this axis, including inhibitors of CD73 and antagonists of the A2A and A2B adenosine receptors, are currently under clinical evaluation. By disrupting adenosine-mediated cAMP signaling, these interventions restore T-cell receptor signaling, cytokine production, and cytotoxic function in both T cells and natural killer cells within adenosine-rich tumor microenvironments. Adenosine pathway inhibitors have shown the greatest efficacy in combination with immune checkpoint blockade, where they relieve parallel inhibitory constraints on effector lymphocytes and enhance responsiveness to PD-1/PD-L1–targeted therapies. Tumors characterized by high levels of DNA damage, nucleotide release, and ectonucleotidase activity are likely to be particularly reliant on adenosine-driven immune evasion, making them rational candidates for adenosine pathway–targeted combination strategies.

Triple Therapy: Chemotherapy, ENPP1/Adenosine Blockade, and Immune Checkpoint Inhibition

DNA-damaging chemotherapy initiates a cascade of immune activation by inducing cytosolic DNA accumulation, immunogenic cell death, and cGAS–STING–dependent type I interferon signaling, thereby promoting antigen release and innate immune priming within the tumor microenvironment. However, these same processes rapidly engage adaptive resistance mechanisms that converge on ENPP1-mediated cGAMP degradation and adenosine-driven suppression of effector immune function. Immune checkpoint inhibitors such as anti PD-1/PD-L1 relieve inhibitory signaling at the level of T-cell activation and exhaustion, but alone they do not counteract upstream constraints on innate immune sensing, antigen presentation, or the metabolic fitness of newly primed effector cells.

Combining chemotherapy with ENPP1 inhibition or blockade of the adenosine pathway preserves and amplifies DNA damage–induced cGAS–STING signaling, prolongs type I interferon production, and sustains dendritic cell activation and antigen cross-presentation. Concurrent attenuation of adenosine-mediated suppression maintains effector T-cell and natural killer cell function within the tumor microenvironment. The addition of immune checkpoint blockade then removes residual inhibitory barriers at the T-cell synapse, enabling newly primed and reinvigorated T cells to expand, infiltrate tumors, and mediate durable cytotoxic responses. By targeting complementary, innate immune activation, metabolic suppression, and adaptive immune inhibition, this triple strategy offers a rational framework for achieving sustained antitumor immunity.

Table 2. Representative Clinical Trials Combining Chemotherapy, Adenosine/ENPP1 Blockade, and Immune Checkpoint Inhibition

Trial / NCT ID	Combination Details	Indication	Trial Stage
ARC-8	Quemliclustat (CD73 inhibitor) + Zimberelimab (anti-PD-1) + Gemcitabine + nab-Paclitaxel	First-line metastatic pancreatic ductal adenocarcinoma	Phase 1b/2
NCT03616886	Oleclumab (anti-CD73) + Durvalumab (anti-PD-L1) + Chemotherapy (e.g., Paclitaxel + Carboplatin)	Advanced solid tumors	Phase II
NCT02503774	Oleclumab + Durvalumab ± Standard chemo in selected cohorts	Advanced / refractory solid tumors	Phase I/II
A2AR + Chemo + PD-1/PD-L1 Arms	A2A receptor antagonists + Checkpoint inhibitors + Chemotherapy	Advanced solid malignancies	Phase I / 1b

Conclusion

DNA-damaging chemotherapies occupy a paradoxical position in cancer immunology, serving as both potent initiators of antitumor immune responses and powerful inducers of immunosuppressive counter-regulatory pathways. Genotoxic stress activates innate immune sensing through the cGAS–STING axis, promotes immunogenic cell death, and enhances antigen availability, collectively fostering conditions favorable for adaptive immune priming. However, these same signals simultaneously engage metabolic and immune checkpoints, most notably ENPP1-mediated degradation of extracellular cGAMP and the accumulation of immunosuppressive adenosine, that restrict dendritic cell function, blunt effector lymphocyte activity, and limit the durability of immune-mediated tumor control.

Recognition of this tightly coupled balance between immune activation and suppression provides a unifying framework for understanding the variable and often transient immunogenicity of chemotherapy. The ENPP1–adenosine axis emerges as a central regulator of this balance, integrating DNA damage–induced innate immune signaling with metabolic mechanisms of immune restraint. Importantly, these suppressive pathways operate upstream of adaptive immune checkpoints, helping to explain why immune checkpoint inhibitors alone frequently fail to fully exploit chemotherapy-induced immune activation.

Therapeutic strategies that disrupt ENPP1 activity or adenosine signaling offer a promising means to sustain cGAS–STING–driven inflammation, preserve antigen presentation, and maintain the functional capacity of effector immune cells within the tumor microenvironment. When combined with immune checkpoint blockade, such approaches have the potential to align innate immune activation, and adaptive immune effector function. Moving forward, rational integration of DNA-damaging chemotherapy with immune checkpoint inhibitors and adaptive immune modulators, guided by biomarkers of DNA damage, nucleotide metabolism, and immune activation, may be essential to convert transient immunogenic effects into durable clinical benefit.

References

Yang H, et al. cGAS–STING in cancer immunity and immunotherapy. Nat Rev Cancer. 2020;20(11):657–674.
Zitvogel L, et al. Mechanisms of immunogenic cell death and implications for cancer immunotherapy. Nat Rev Immunol. 2021;21(12):749–772.
Vijayan D, et al. Targeting the adenosine pathway for cancer immunotherapy. Nat Rev Cancer. 2020;20(10):608–624.
Allard B, et al. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611–629.
Burnstock G, et al. Purinergic signaling and cancer. Trends Cancer. 2021;7(5):457–475.
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with chemo- and radio-therapy. Immunity. 2020;52(5):917–943.

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI).

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.